Analyst Issues Sell Rating for GlaxoSmithKline Amid Legal Challenges and Financial Risks
Barclays Remains a Hold on GlaxoSmithKline (GSK)
Goldman Sachs Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
Berenberg Bank Maintains GlaxoSmithKline(GSK.US) With Buy Rating, Maintains Target Price $46
Argus Research Remains a Buy on GlaxoSmithKline (GSK)
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
Citi Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)
Kepler Capital Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
BofA Securities Maintains GlaxoSmithKline(GSK.US) With Sell Rating
Bank of America Securities Sticks to Their Sell Rating for GlaxoSmithKline (GSK)
Deutsche Bank Keeps Their Buy Rating on GlaxoSmithKline (GSK)
J.P. Morgan Keeps Their Sell Rating on GlaxoSmithKline (GSK)
GlaxoSmithKline Sell Rating Justified by Arexvy Underperformance and Reduced Revenue Projections
GlaxoSmithKline (GSK) Receives a Buy From Jefferies
GlaxoSmithKline (GSK) Receives a Buy From Deutsche Numis
Citi Sticks to Their Buy Rating for GlaxoSmithKline (GSK)
UBS Sticks to Its Buy Rating for GlaxoSmithKline (GSK)
GSK Analyst Ratings
Jefferies Maintains Buy on GSK, Raises Price Target to $53
J.P. Morgan Keeps Their Sell Rating on GlaxoSmithKline (GSK)